Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Ongoing challenges for pharmacotherapy for dyslipidemia
Author: Pisaniello, A.
Scherer, D.
Kataoka, Y.
Nicholls, S.
Citation: Expert Opinion on Pharmacotherapy, 2015; 16(3):347-356
Publisher: Taylor and Francis
Issue Date: 2015
ISSN: 1465-6566
Statement of
Anthony D Pisaniello, Daniel J Scherer, Yu Kataoka and Stephen J Nicholls
Abstract: Introduction: While increasing evidence has led to lipid-modifying therapy achieving an important role in the treatment guidelines for the prevention of cardiovascular disease, these agents are suboptimally used and there remains a considerable risk of clinical events. Accordingly, there is a need to develop more effective lipid-modifying approaches in many patients. Areas covered: A literature search was performed of topical manuscripts focusing on factors influencing use of established therapies and new agents in development that target a range of lipid factors. Expert opinion: More intensive efforts are required to ensure that statin use is maximized in higher risk patients. A range of novel therapies, including proprotein convertase subtilisin kexin-type 9 and cholesteryl ester transfer protein inhibitors, may provide additional protection, although this remains to be established by clinical trials.
Keywords: Atherosclerosis; cardiovascular risk; lipid-modifying therapy; lipids
Rights: © 2015 Informa UK, Ltd. ISSN 1465-6566, e-ISSN 1744-7666 All rights reserved: reproduction in whole or in part not permitted
RMID: 0030017476
DOI: 10.1517/14656566.2014.986094
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.